Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The best-performing US big cap biopharma company this year still has lots of room to grow, according to brokers. Eli Lilly and Co (NYSE:LLY) “still offers one of the cleanest, de-risked growth stories” in the large cap pharmaceutical space, UBS analysts wrote in a note this week.

Eli Lilly is the best-performing big cap pharma stock this year for a reason, analysts say

Eli Lilly & Co (NYSE: LLY) has rallied over the past three months but a Bank of America analyst says it's not out of room to run just yet.

Eli Lilly stock price forecast ahead of obesity drug approval

Amazon

Alphabet

ServiceNow

BYD Company Limited

Merck

NVIDIA

As someone who has been writing about stocks professionally for 18 years, I remember when Microsoft (NASDAQ: MSFT ), Amazon (NASDAQ: AMZN ) and Apple (NASDAQ: AAPL ) were the first companies with $1 trillion market capitalizations. There was a great deal of fascination with the milestones at the time.

7 Stocks That Could Be the Next $2 Trillion-Dollar Companies

Cigna

DexCom

Elevance Health Inc

Exact Sciences

Humana

UnitedHealth Group

The Baron Health Care Fund's first five years have been exceptional in every sense of the word. Launched in spring 2018, the fund has navigated around the COVID-19 pandemic, a biotech initial public offering market that boomed and fizzled, and D.C.

These stock pickers led the health-fund category over the past 5 years. Here's where they're investing now.

Reduced greenhouse gas emissions by 20% Improved access to Lilly insulins in the U.S. Nearly doubled patients reached in resource-limited settings through global health efforts INDIANAPOLIS , May 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's ambitious sustainability goals, which are critical to maintaining a strong and resilient company. Notable sustainability highlights in the report include: Reducing greenhouse gas emissions in the company's operations by more than 20% from 2020 to 2022 despite significant business growth over the same timeframe.

Lilly ESG Report Highlights Progress Towards Sustainability Goals

Capital One

Momentum stocks are securities that are rising fast and seeing their gains accelerate. This is often because a given stock has one or more catalysts that have led to a rally in its share price.

The 3 Best Momentum Stocks to Buy in May 2023

GREENVILLE, S.C.--(BUSINESS WIRE)--Southern Tide, the premier coastal lifestyle and apparel brand, and Lilly Pulitzer, the leader in women's resort wear, have partnered to launch a men's and youth capsule collection. This collection celebrates Lilly Pulitzer's introduction to the menswear category by combining the well-known brand's iconic resort prints with Southern Tide's signature silhouettes. “We are thrilled to work alongside the creatives at Lilly Pulitzer as they make their debut into me.

Southern Tide and Lilly Pulitzer Launch South Carolina-Inspired Capsule Collection

Biogen

Biogen and Eli Lilly both have promising Alzheimer's drugs that have shown they are effective in slowing the rate of cognitive decline in patients. They both come with risks related to brain swelling and brain bleeding, and trial participants have died.

1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market

Novartis

Big pharmaceutical stocks, including Novartis AG NYSE: NVS, Eli Lilly & Co. NYSE: LLY, Merck & Co. NYSE: MRK, and Novo Nordisk A/S NYSE: NVO have been outperforming the broader market recently, even as the healthcare sector as a whole lags.

Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market

Eli Lilly & Co. LLY, +0.19% said Thursday a mid-stage trial of a treatment for rheumatoid arthritis met its main goal for efficacy with similar rates of adverse events between the treatment group and placebo arms. The data was published in the The New England Journal of Medicine.

Eli Lilly says mid-stage trial of rheumatoid arthritis met its main efficacy goal

Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA) Study evaluated a novel approach to treating patients with autoimmune diseases INDIANAPOLIS , May 18, 2023 /PRNewswire/ -- The New England Journal of Medicine  today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in rheumatoid arthritis (RA), in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms. These data represent the first clinical evidence that stimulating the endogenous PD-1 inhibitory pathway could be an effective approach to treat rheumatologic disease.

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine

Cardinal Health

Everyone seems to be talking about semiconductors, artificial intelligence (AI) and mega-cap tech. However, no one seems to be talking about healthcare stocks to buy.

Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs

If Eli Lilly stays around 440, this calendar spread profits on its neutral outlook. The post Eli Lilly Stock Doesn't Have To Shoot Higher For Profits appeared first on Investor's Business Daily.

Eli Lilly Stock Doesn't Have To Shoot Higher For Profits

ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Collaboration combines Scribe's CRISPR by Design™ approach with Prevail's expertise in developing genetic medicines for neurological disorders.

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

Chipotle

ONEOK

Ross Stores

CNBC's Jim Cramer is looking to 2011 for investing guidance during the ongoing debt ceiling uncertainty.

Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth

American Express

bluebird bio

Discover

Goldman Sachs

ImmunoGen

SoFi Technologies

The Regional Bank Fiasco is a classic “Baby with the Bathwater” scenario. Rising rates are great for Insurance companies and “hidden banks”.

Tech Titans Aren't The Only Game In Town, Consider Biotech And, Yes, Financials

Eli Lilly and Company (NYSE:LLY ) Bank of America Securities 2023 Healthcare Conference May 10, 2023 1:00 PM ET Company Participants Patrik Jonsson - Executive Vice President, President-Lilly Immunology, President-Lilly USA & Chief Customer Officer Conference Call Participants Geoff Meacham - BofA Geoff Meacham Okay. Welcome to the second day of the BofA Healthcare Conference.

Eli Lilly and Company (LLY) Presents at Bank of America Securities 2023 Healthcare Conference

Two new medicines are going to compete for the Alzheimer's therapy market. Eli Lilly's candidate appears to be more effective, but it isn't approved yet.

These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win

Axsome Therapeutics

Vertex Pharmaceuticals

Axsome's relatively new approval was only the first step in an exciting growth story. Eli Lilly has a strong pipeline that will help improve its already-solid financial results.

3 Growth Stocks to Buy and Hold

The market is pricing Eli Lilly's stock as if its earnings are going to grow like wild, and they might. Its pipeline could furnish the company with plenty of near-term growth.

Will Eli Lilly Be a Trillion-Dollar Stock by 2030?

Johnson & Johnson

Eli Lilly & Co. was on track Friday to close with a greater market capitalization than Johnson & Johnson for the first time since October 1997, according to Dow Jones Market Data.

Eli Lilly on track to close with a higher market cap than J&J for first time since 1997

Novo Nordisk

Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.

Weight-loss drug developers line up to tap market worth $150 billion

Viking Therapeutics

Viking Therapeutics said on Tuesday its experimental drug helped patients with obesity achieve "significant" weight loss in a mid-stage study.

News for Eli Lilly Stock (LLY)